1
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, June 11, 1991: US05023269 (65 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


2
Edward E Beedle, David W Robertson, David T Wong: Serotonin antagonists. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, May 7, 1991: US05013761 (60 worldwide citation)

This invention provides a method of selectively antagonizing the 5-HT.sub.1A receptor in mammals by administering aryloxypropanolamines. Novel aryloxypropanolamines are also claimed.


3
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, September 11, 1990: US04956388 (56 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


4
James E Audia, David J Hibschman, Joseph H Krushinski Jr, Thomas E Mabry, Jeffrey S Nissen, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson, David T Wong: Compounds having effects on serotonin-related systems. Eli Lilly and Company, Joseph A Jones, David E Boone, May 6, 1997: US05627196 (47 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


5
James E Audia, Joseph H Krushinski Jr, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson, David T Wong: Compounds having effects on serotonin-related systems. Eli Lilly and Company, Joseph A Jones, David E Boone, March 25, 1997: US05614523 (39 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


6
David T Wong, Juan I Oguiza: Potentiation of drug response. Eli Lilly and Company, Joseph A Jones, David E Boone, July 2, 1996: US05532244 (39 worldwide citation)

The power of fluoxetine, venlafaxine, milnacipran and duloxetine to increase the availability of serotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.


7
James E Audia, David J Hibschman, Joseph H Krushinski Jr, Thomas E Mabry, Jeffrey S Nissen, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson, David T Wong: Compounds having effects on serotonin-related systems. Eli Lilly Company, Arleen Palmberg, David E Boone, August 4, 1998: US05789402 (37 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


8
David T Wong, Juan I Oguiza: Potentiation of drug response. Eli Lilly and Company, Joseph A Jones, David E Boone, September 3, 1996: US05552429 (22 worldwide citation)

The power of fluoxetine, venlafaxine, milnacipran and duloxetine to increase the availability of serotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.


9

10


Click the thumbnails below to visualize the patent trend.